These days, many start-ups aim to improve upon existing drugs, and swipe some of their market share, by dint of novel delivery methods. Macroflux has those aspirations, and considerably more means to realize them than most firms founded just six months ago. The company is a spin-out from J&J's Alza Corp., one of the most productive drug delivery outfits ever. Macroflux will commercialize a patch-based drug delivery system that the company expects will be a virtually painless way to deliver therapeutic proteins, peptides, and vaccines.
2000 Charleston Road
Mountain View, CA 94043
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
